We included all studies that met the following criteria: (1) observational studies or RCTs comparing recombinant tissue-type plasminogen activator (r-tPA) and DAPT in patients with mild stroke and (2) studies reporting the required outcomes. This evidence concerns the gene PLAT and stroke disorder.